Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Recruiting now

Conditions studied: Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma

In brief

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Key facts

Study ID

NCT05011045

Run by

M.D. Anderson Cancer Center

People needed

100

Starts

2020-01-09

Expected to finish

2026-10-31

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma [PCNSL], secondary central nervous system lymphoma [SCNSL], leukemia, myeloma)
• Proficient and capable of completing tests in English
• Patients with claustrophobia are eligible if the claustrophobia is managed with medication
• Patients with cognitively-impairment are eligible if the impairment is managed with medication
• Patients who are pregnant

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.